Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Cater

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
European Heart Journal|October 21, 2023
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trialAmbarish Pandey, Ahmed A Kolkailah, Francesco Cosentino, et al.
Diabetes, Obesity & Metabolism|January 3, 2023
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular diseaseJoseph M Kim, Deepak L Bhatt, Samuel Dagogo-Jack, et al.
Circulation|October 7, 2020
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV TrialFrancesco Cosentino, Christopher P Cannon, David Z I Cherney, et al.
European Journal of Heart Failure|January 10, 2025
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trialAmbarish Pandey, Ahmed A Kolkailah, Darren K McGuire, et al.
Journal of Clinical Lipidology|September 17, 2024
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round TableFrançois Mach, Frank L J Visseren, Nilo B Cater, et al.
Circulation|June 4, 2008
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatmentJohn J P Kastelein, Wim A van der Steeg, Ingar Holme, et al.
Diabetes, Obesity & Metabolism|May 23, 2022
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitusMatthew W Segar, Ahmed A Kolkailah, Robert Frederich, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
European Heart Journal|October 21, 2023
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trialAmbarish Pandey, Ahmed A Kolkailah, Francesco Cosentino, et al.
Diabetes, Obesity & Metabolism|January 3, 2023
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular diseaseJoseph M Kim, Deepak L Bhatt, Samuel Dagogo-Jack, et al.
Circulation|October 7, 2020
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV TrialFrancesco Cosentino, Christopher P Cannon, David Z I Cherney, et al.
European Journal of Heart Failure|January 10, 2025
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trialAmbarish Pandey, Ahmed A Kolkailah, Darren K McGuire, et al.
Journal of Clinical Lipidology|September 17, 2024
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round TableFrançois Mach, Frank L J Visseren, Nilo B Cater, et al.
Circulation|June 4, 2008
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatmentJohn J P Kastelein, Wim A van der Steeg, Ingar Holme, et al.
Diabetes, Obesity & Metabolism|May 23, 2022
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitusMatthew W Segar, Ahmed A Kolkailah, Robert Frederich, et al.
Pageof 6